BTG.L on London Stock Exchange

29 May 2015
Change (% chg)

-14.00p (-1.93%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for BTG.L


BTG plc is a United Kingdom-based specialist healthcare company focused on developing and commercializing products targeting acute care, cancer and vascular diseases. The Company operates in three business segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing. Its Interventional Medicines include Interventio... (more)


Beta: 0.39
Market Cap(Mil.): £2,763.82
Shares Outstanding(Mil.): 382.01
Dividend: --
Yield (%): --


  BTG.L Industry Sector
P/E (TTM): 80.53 36.11 38.09
EPS (TTM): 0.09 -- --
ROI: 4.32 16.12 15.45
ROE: 5.21 16.91 16.49
Search Stocks

Britain's BTG sees two-year build-up for varicose vein product

LONDON, May 19 - British pharmaceutical company BTG said its full-year profit was dampened by investment in new products, including its Varithena varicose veins treatment in the United States.

19 May 2015

BRIEF-BTG full-year profit dips on investments, acquisitions

* Fy pretax profit 26.7 million stg versus 33.3 million stg year ago

19 May 2015

British drugs firm BTG lifts 2014/15 sales forecast

LONDON, April 2 - British drugs company BTG nudged up its 2014/15 revenue forecast on Thursday and said it was on course for further strong growth in its new financial year.

02 Apr 2015

BRIEF-Britihs pharma co BTG launches ADR programme

* Adr programme will be open for deposits from 9 a.m. (est) today Source text for Eikon: Further company coverage:

19 Feb 2015

British drugs company BTG lifts revenue guidance

LONDON, Feb 5 - British drugs company BTG lifted its forecast for annual revenues by as much as 4 percent on Thursday, citing the benefits of a U.S. acquisition and the reversal of currency headwinds.

05 Feb 2015

BRIEF-BTG raises full-year revenue forecast

* Full year revenue is now expected to be in range 345 mln-360 mln stg; previous guidance was 330 mln-345 mln stg

05 Feb 2015

BRIEF-BTG raises about 150 mln stg by placing new shares

* Placing raised proceeds of approximately 150 mln stg (before expenses)

04 Dec 2014

CORRECTED-BRIEF-BTG to acquire Pneumrx for up to $475 mln, funded by placing

* Announce that it has entered into an agreement to acquire pneumrx inc on a debt free cash free basis for an initial cash consideration of us$230 million

04 Dec 2014

BTG to buy lung intervention firm for up to $475 mln

LONDON, Dec 4 - BTG, the healthcare group best known for treating rattlesnake bites and varicose veins, is expanding into lung care by buying a Californian firm that has developed a device to prop open airways.

04 Dec 2014

Earnings vs. Estimates

Search Stocks